Martin Comtesse, an analyst from Jefferies, maintained the Buy rating on Redcare Pharmacy (0RJT – Research Report). The associated price target remains the same with €170.00.
Martin Comtesse’s rating is based on a combination of factors that highlight the potential for Redcare Pharmacy’s stock. The company’s intensified marketing efforts have led to a significant boost in revenue, although this has slightly impacted profitability for the fiscal year 2024. Despite this, the guidance for fiscal year 2025 presents a positive outlook, with adjusted EBITDA projections exceeding market expectations by 20% at the midpoint.
Furthermore, the anticipated margin range of 2.0-2.5% is more favorable than recent market concerns had suggested. The expectation of a strong first-quarter performance, driven by flu and prescription sales, could serve as a pivotal moment for Redcare Pharmacy, reinforcing the Buy rating given by Martin Comtesse.
In another report released on February 28, Hauck & Aufhaeuser also maintained a Buy rating on the stock with a €175.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com